NCT02628665

Brief Summary

The therapy of photofrin PDT was effective in improving life quality of patients with advanced esophageal and/or gastric cardiac cancer and the time optimizing for employing laser irradiation was of great importance.The purpose of this study is to evaluate the clinical efficacy and adverse effects of Photodynamic Therapy (PDT) on esophageal and/or gastric cardiac cancer during different time after inject photofrin.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Oct 2015

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 27, 2015

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 11, 2015

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2017

Completed
2.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

December 11, 2015

Status Verified

October 1, 2015

Enrollment Period

2 years

First QC Date

November 27, 2015

Last Update Submit

December 10, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Partial remission rate

    Photodynamic therapy for 3 months after the review of gastroscope for pathologic examination, to check the response rate

    3 months

Secondary Outcomes (1)

  • The recent incidence of adverse reactions

    7-10 days

Study Arms (2)

24 to 48 hours group

EXPERIMENTAL

photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 24 to 48 hours: The injection of photosensitizer(photofrin) 24 to 48 hours light irradiation power. 630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.

Drug: photosensitizer(photofrin)Device: 630 nm laser irradiation (DIOMED)

48 to 72 hours group

ACTIVE COMPARATOR

photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 48 to 72 hours: The injection of photosensitizer(photofrin) 48 to 72 hours light irradiation power. 630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.

Drug: photosensitizer(photofrin)Device: 630 nm laser irradiation (DIOMED)

Interventions

photosensitizer(photofrin): 2mg/kg

Also known as: photofrin
24 to 48 hours group48 to 72 hours group

630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.

Also known as: DIOMED
24 to 48 hours group48 to 72 hours group

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • In the esophagus, patients with severe dysplasia and carcinoma in situ
  • The patients have not received the surgery or chemo-radiotherapy.
  • Hb≥80g/L, absolute neutrophil count ≥1.5×109/L, Plt≥90×109/L, ALT、AST≤2.5\*N,Cr≤1.5\*N.
  • Performance status score 0-2

You may not qualify if:

  • pregnant, lactating women
  • History of organ transplantation
  • The peripheral nervous system disorders
  • Severe infection
  • Oral capecitabine who have difficulty with,such as dysphagia,The activities of digestive ulcer, Gastrointestinal bleeding
  • Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high blood pressure, diabetes.
  • Other malignant tumor in recent 5 years.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, 471003, China

RECRUITING

Related Publications (2)

  • Lindenmann J, Matzi V, Neuboeck N, Anegg U, Baumgartner E, Maier A, Smolle J, Smolle-Juettner FM. Individualized, multimodal palliative treatment of inoperable esophageal cancer: clinical impact of photodynamic therapy resulting in prolonged survival. Lasers Surg Med. 2012 Mar;44(3):189-98. doi: 10.1002/lsm.22006. Epub 2012 Feb 14.

    PMID: 22334351BACKGROUND
  • Yano T, Muto M, Minashi K, Iwasaki J, Kojima T, Fuse N, Doi T, Kaneko K, Ohtsu A. Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int J Cancer. 2012 Sep 1;131(5):1228-34. doi: 10.1002/ijc.27320. Epub 2012 Mar 2.

    PMID: 22024814BACKGROUND

MeSH Terms

Conditions

Adenocarcinoma Of EsophagusEsophageal Squamous Cell Carcinoma

Interventions

Dihematoporphyrin Ether

Condition Hierarchy (Ancestors)

Carcinoma, Squamous CellCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, Squamous CellEsophageal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal Diseases

Intervention Hierarchy (Ancestors)

Hematoporphyrin DerivativeHematoporphyrinsPorphyrinsTetrapyrrolesPyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingMacrocyclic CompoundsPolycyclic CompoundsPigments, BiologicalBiological Factors

Study Officials

  • Shegan Gao, Doctor

    The First Affiliated Hospital of Henan University of Science and Technology

    STUDY CHAIR
  • Tanyou Shan, Master

    The First Affiliated Hospital of Henan University of Science and Technology

    STUDY DIRECTOR
  • Caihong Dong, Master

    The First Affiliated Hospital of Henan University of Science and Technology

    PRINCIPAL INVESTIGATOR
  • Xiaozhi Yuan, Master

    The First Affiliated Hospital of Henan University of Science and Technology

    PRINCIPAL INVESTIGATOR
  • Lin Guo, Bachelor

    The First Affiliated Hospital of Henan University of Science and Technology

    PRINCIPAL INVESTIGATOR
  • Lijuan Zhang, Bachelor

    The First Affiliated Hospital of Henan University of Science and Technology

    PRINCIPAL INVESTIGATOR
  • Gailin Wang, Bachelor

    The First Affiliated Hospital of Henan University of Science and Technology

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shegan Gao, Doctor

CONTACT

Tanyou Shan, Master

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 27, 2015

First Posted

December 11, 2015

Study Start

October 1, 2015

Primary Completion

October 1, 2017

Study Completion

December 1, 2019

Last Updated

December 11, 2015

Record last verified: 2015-10

Locations